End-of-day quote
Korea S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
2,340
KRW
|
+2.86%
|
|
-11.36%
|
+9.86%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
197,110
|
124,311
|
172,971
|
239,297
|
112,271
|
68,746
|
Enterprise Value (EV)
1 |
223,685
|
145,168
|
204,069
|
232,510
|
132,911
|
56,129
|
P/E ratio
|
-11.4
x
|
-4.33
x
|
-6.16
x
|
-10.6
x
|
-4.45
x
|
8.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.29
x
|
1.71
x
|
2.15
x
|
2.37
x
|
1.12
x
|
3.77
x
|
EV / Revenue
|
2.6
x
|
1.99
x
|
2.54
x
|
2.3
x
|
1.32
x
|
3.08
x
|
EV / EBITDA
|
-163
x
|
-11.1
x
|
-33.6
x
|
-29.6
x
|
-16.9
x
|
54.5
x
|
EV / FCF
|
-11.4
x
|
-7.76
x
|
-5.9
x
|
-38.2
x
|
-15.9
x
|
4.25
x
|
FCF Yield
|
-8.77%
|
-12.9%
|
-16.9%
|
-2.62%
|
-6.3%
|
23.5%
|
Price to Book
|
8.39
x
|
5.22
x
|
5.65
x
|
5.42
x
|
5.25
x
|
2.08
x
|
Nbr of stocks (in thousands)
|
15,960
|
17,683
|
27,412
|
28,658
|
31,449
|
32,275
|
Reference price
2 |
12,350
|
7,030
|
6,310
|
8,350
|
3,570
|
2,130
|
Announcement Date
|
3/15/19
|
3/18/20
|
3/19/21
|
3/23/22
|
3/23/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
86,067
|
72,877
|
80,453
|
101,170
|
100,413
|
18,245
|
EBITDA
1 |
-1,370
|
-13,113
|
-6,065
|
-7,850
|
-7,857
|
1,031
|
EBIT
1 |
-5,557
|
-18,075
|
-11,958
|
-14,651
|
-14,591
|
-5,164
|
Operating Margin
|
-6.46%
|
-24.8%
|
-14.86%
|
-14.48%
|
-14.53%
|
-28.3%
|
Earnings before Tax (EBT)
1 |
-16,542
|
-41,308
|
-31,691
|
-36,736
|
-34,990
|
-6,139
|
Net income
1 |
-17,228
|
-28,046
|
-21,138
|
-19,768
|
-23,137
|
8,009
|
Net margin
|
-20.02%
|
-38.48%
|
-26.27%
|
-19.54%
|
-23.04%
|
43.9%
|
EPS
2 |
-1,081
|
-1,622
|
-1,024
|
-790.2
|
-802.1
|
249.0
|
Free Cash Flow
1 |
-19,607
|
-18,713
|
-34,587
|
-6,094
|
-8,373
|
13,211
|
FCF margin
|
-22.78%
|
-25.68%
|
-42.99%
|
-6.02%
|
-8.34%
|
72.41%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
1,281.98%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
164.96%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/19
|
3/18/20
|
3/19/21
|
3/23/22
|
3/23/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
26,575
|
20,857
|
31,098
|
-
|
20,639
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
6,787
|
-
|
12,617
|
Leverage (Debt/EBITDA)
|
-19.4
x
|
-1.591
x
|
-5.128
x
|
-
|
-2.627
x
|
-
|
Free Cash Flow
1 |
-19,607
|
-18,713
|
-34,587
|
-6,094
|
-8,373
|
13,211
|
ROE (net income / shareholders' equity)
|
-31.3%
|
-65.3%
|
-44%
|
-37.3%
|
-40.7%
|
-11.9%
|
ROA (Net income/ Total Assets)
|
-3.64%
|
-7.5%
|
-4.41%
|
-4.83%
|
-5.41%
|
-3.27%
|
Assets
1 |
473,371
|
374,134
|
479,129
|
409,666
|
427,858
|
-245,040
|
Book Value Per Share
2 |
1,472
|
1,347
|
1,116
|
1,541
|
680.0
|
1,022
|
Cash Flow per Share
2 |
2,400
|
2,459
|
1,395
|
2,063
|
386.0
|
587.0
|
Capex
1 |
4,061
|
23,502
|
17,783
|
1,767
|
1,717
|
339
|
Capex / Sales
|
4.72%
|
32.25%
|
22.1%
|
1.75%
|
1.71%
|
1.86%
|
Announcement Date
|
3/15/19
|
3/18/20
|
3/19/21
|
3/23/22
|
3/23/23
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| +9.86% | 62.78M | | +30.92% | 682B | | +30.35% | 586B | | -3.49% | 364B | | +18.16% | 327B | | +4.04% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +8.13% | 165B |
Other Pharmaceuticals
|